Stromal cells promote bone invasion by suppressing bone formation in ameloblastoma

Histopathology

Volumn 53, Issue 4, 2008, Pages 458-467

  Sathi, G S A ^a   Nagatsuka, H ^a   Tamamura, R ^a   Fujii, M ^a   Gunduz, M ^a   Inoue, M ^a   Rivera, R S ^a   Nagai, N ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Ameloblastoma; Osteoblast; Osteoclast; SFRP 2; Stroma

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; CD68 ANTIGEN; INTERLEUKIN 6; MONOCLONAL ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; POLYCLONAL ANTIBODY; SECRETED FRIZZLED RELATED PROTEIN 2; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AMELOBLASTOMA; ARTICLE; CELL INTERACTION; CLINICAL ARTICLE; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MANDIBLE; MAXILLA; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; PRIORITY JOURNAL; STROMA; STROMA CELL; TUMOR CELL; TUMOR LOCALIZATION;

ADULT; AMELOBLASTOMA; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BONE AND BONES; BONE NEOPLASMS; BONE RESORPTION; FEMALE; HUMANS; INTERLEUKIN-6; JAW NEOPLASMS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM INVASIVENESS; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS; RANK LIGAND; STROMAL CELLS; TUMOR CELLS, CULTURED;

EID: 52749088805     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2008.03127.x     Document Type: Article

References (36)

1. Shafer WG, Hine MK, Levy BM. Cyst and tumors of odontogenic origin. In Shafer WG, Hine MK, Levy BM ed. A textbook of oral pathology, 4th edn. Philadelphia, USA: W.B. Saunders Co., 1983 258 317.
2. Suda T, Takahashi N, Martin TJ. Modulation of osteoclast differentiation. Endocr. Rev. 1992 13 66 80.
3. Guise TA, Mohammad KS, Clines G et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res. 2006 12 (20 Pt 2 6213s 6216s.
4. Bodine PV, Komm BS. Wnt signaling and osteoblastogenesis. Rev. Endocr. Metab. Disord. 2006 7 33 39.
5. Oshima T, Abe M, Asano J et al. Myeloma cells suppress bone formation by secreting soluble Wnt inhibitor sFRP-2. Blood 2005 106 3160 3165.
6. Kawano Y, Kypta R. Secreted antagonists of the Wnt signalling pathway. J. Cell Sci. 2003 116 (Pt 13 2627 2634.
7. Etheridge SL, Spencer GJ, Heath DJ, Genever PG. Expression profiling and functional analysis of Wnt signaling mechanisms in mesenchymal stem cells. Stem Cells 2004 22 849 860.
8. Rattner A, Hsieh JC, Smallwood PM et al. A family of secreted proteins contains homology to the cysteine-rich ligand-binding domain of frizzled receptors. Proc. Natl Acad. Sci. USA 1997 94 2859 2863.
9. Abe E. Function of BMPs and BMP antagonists in adult bone. Ann. NY Acad. Sci. 2006 1068 41 53.
10. Ten Dijke P, Fu J, Schaap P, Roelen BAJ. Signal transduction of bone morphogenetic proteins in osteoblast differentiation. J. Bone Joint Surg. Am. 2003 85-A 33 38.
11. Chen Y, Whetstone HC, Youn A et al. Beta-catenin signaling pathway is crucial for bone morphogenetic protein 2 to induce new bone formation. J. Biol. Chem. 2007 282 526 533.
12. Anderson MA, Maraskovsky E, Billingsley WL et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997 390 175 179.
13. Lacey DL, Timms E, Tan HL et al. Osteoprotegerin (OPG) ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998 93 165 176.
14. Hsu H, Lacey DL, Dunstan CR et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc. Natl Acad. Sci. USA 1999 96 3540 3545.
15. Simonet WS, Lacey DL, Dunstan CR et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997 89 309 319.
16. McHugh KP, Keith RS, Peter VH. New developments in the biology of osteoclasts and osteoblasts. The Harvard Orthopaedic Journal Online 2000 2 11 online (http://www.orthojournalhms.org/volume2/html/articles11.htm).
17. Wada T, Nakashima T, Hiroshi N, Penninger JM. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol. Med. 2006 12 17 25.
18. Tay JY, Bay BH, Yeo JF, Harris M, Meghji S, Dheen ST. Identification of RANKL in osteolytic lesions of the facial skeleton. J. Dent. Res. 2004 83 349 353.
19. Sandra F, Hendarmin L, Kukita T et al. Ameloblastoma induces osteoclastogenesis: a possible role of ameloblastoma in expanding in the bone. Oral Oncol. 2005 41 637 644.
20. Kumamoto H, Ooya K. Expression of parathyroid hormone-related protein (PTHrP), osteoclast differentiation factor (ODF)/receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoclastogenesis inhibitory factor (OCIF)/osteoprotegerin (OPG) in ameloblastomas. J. Oral Pathol. Med. 2004 33 46 52.
21. Karsdal MA, Hjorth P, Henriksen K et al. Transforming growth factor-β controls human osteoclastogenesis through the p38 MAPK and regulation of RANK expression. J. Biol. Chem. 2003 278 44975 44987.
22. Kaneda T, Nojima T, Nakagawa M et al. Endogenous production of TGF-beta is essential for osteoclastogenesis induced by a combination of receptor activator of NF-kappa B ligand and macrophage-colony-stimulating factor. J. Immunol. 2000 165 4254 4263.
23. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature 2004 432 332 337.
24. Karnoub AE, Dash AB, Vo AP et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007 449 557 563.
25. Mueller MM, Fusenig NE. Tumor-stroma interactions directing phenotype and progression of epithelial skin tumor cells. Differentiation 2002 70 486 497.
26. Noel A, Gilles C, Bajou K et al. Emerging roles for proteinases in cancer. Invasion Metastasis 1997 17 221 239.
27. Pinheiro JJ, Freitas VM, Moretti AI, Jorge AG, Jaeger RG. Local invasiveness of ameloblastoma role played by matrix metalloproteinases and proliferative activity. Histopathology 2004 45 65 72.
28. Nagatsuka H, Han PP, Tsujigiwa H et al. Heparanase gene and protein expression in ameloblastoma: possible role in local invasion of tumor cells. Oral Oncol. 2005 41 542 548.
29. Watanabe M, Miura H, Inoue H et al. Mixed osteoclastic/pleomorphic-type giant cell tumor of the pancreas with ductal adenocarcinoma: histochemical and immunohistochemical study with review of the literature. Pancreas 1997 15 201 208.
30. Junqueira LC, Carneiro J, Kelley RO. Bone. In Junqueira LC, Carneiro J, Kelley RO ed. Basic histology, 9th edn. Stamford, USA: A Simon and Schuster Co., 1998 134 151.
31. Mangham DC, Scoones DJ, Drayson MT. Complement and the recruitment of mononuclear osteoclasts. J. Clin. Pathol. 1993 46 517 521.
32. Roth W, Wild-Bode C, Platten M et al. Secreted frizzled-related proteins inhibit motility and promote growth of human malignant glioma cells. Oncogene 2000 19 4210 4220.
33. Sathi GS, Han PP, Tamamura R et al. Immunolocalization of cell signaling molecules in the granular cell ameloblastoma. J. Oral Pathol. Med. 2007 36 609 614.
34. Han PP, Nagatsuka H, Tamamura R et al. Role of heparanase in the release of heparan sulphate binding growth factors in odontogenic tumors. J. Hard Tissue Biol. 2007 16 23 30.
35. Janssens K, Ten Dijke P, Janssens S, Van Hul W. Transforming growth factor-beta1 to the bone. Endocr. Rev. 2005 26 743 774.
36. Kominsky SL, Doucet M, Brady K, Weber KL. TGF-beta promotes the establishment of renal cell carcinoma bone metastasis. J. Bone Miner. Res. 2007 22 37 44.